Articles tagged with Malaria
A new study reveals that climate change could lead to a shift in malaria transmission patterns across Africa, with southern Africa experiencing increases in suitable areas and West Africa seeing decreases. River corridors are identified as year-round hot spots of malaria transmission.
Researchers discovered new types of mosquito immune cells and molecular pathways implicated in controlling the malaria parasite. A rare cell type called a Megacyte was found to have high levels of a key molecule needed for immune priming, which could limit malaria transmission.
Researchers have created a genetically engineered mosquito strain with a Cas9/guide RNA-based gene drive that targets the cardinal gene to prevent malaria transmission. The drive achieved an average efficiency of 96.7% in both sexes, ensuring every mosquito carries at least one copy within six generations.
Researchers found a higher prevalence of anemia in pregnant women with malaria and HIV coinfections compared to those without infections. The study suggests that multipronged strategies to prevent and treat these infections are critical to ensure the survival of mothers and their unborn babies.
A three-year intervention in southern Mozambique averted almost 40,000 malaria cases and reduced disease transmission by 85%. Despite this drastic reduction, the study finds that disease transmission was not interrupted, highlighting the need for new strategies to achieve elimination.
The emergence of artemisinin-resistant malaria parasites in Rwanda marks a major concern for global health. Significant proportions of parasites carrying the R561H mutation have been detected, indicating that these resistant strains can spread between locations and acquire resistance to partner drugs.
Researchers discovered new channels enabling lipid transport between the malaria parasite and red blood cells, raising possibility of nutrient-blocking treatments. The study found Niemann-Pick C1-related protein (PfNCR1) channels made of PfNCR1.
Research reveals insecticide-treated mosquito nets, crucial in global malaria fight, have lost significant protection effectiveness. Long-lasting insecticidal nets (LLINs), credited with saving millions lives since 2000, are now only killing 40% of mosquitoes they come into contact with.
A modelling study predicts that COVID-19 could lead to a significant increase in HIV, TB, and malaria deaths in low- and middle-income countries. The study suggests that prioritizing antiretroviral therapy, timely diagnosis and treatment of TB, and long-lasting insecticide-treated nets could mitigate the impact of the pandemic.
A new approach developed by Kyoto University scientists provides insight into the liver stage of the Plasmodium vivax malaria parasite. The method involves infecting human liver cells with mosquito-bred parasites, enabling researchers to study the parasite's life cycle and develop more effective treatments.
Researchers at the Francis Crick Institute have identified a protein used by the malaria parasite to protect itself from toxic compounds in red blood cells. This discovery could lead to the development of drugs that block this process, potentially providing valuable insights for treating malaria.
A recent study mapped mosquito insecticide resistance patterns across Africa, finding dramatic increases in resistance to five mainstream insecticides between 2005 and 2017. This surge in resistance poses a significant threat to malaria control efforts, particularly in Sub-Saharan Africa where over half of all cases occur.
Scientists at Seattle Children's Research Institute have developed a genetically attenuated parasite (GAP) that arrests late in the liver stage of human malaria, paving the way for a novel next-generation vaccine. The GAP technology has the potential to offer protection to those living in regions where malaria transmission is widespread.
A research team at ISGlobal has developed a system to induce massive sexual conversion of the P. falciparum malaria parasite in vitro, enabling deeper understanding and design of new tools to block malaria transmission. This technique allows for synchronization of parasites at the initial stages of sexual development.
A new tetrahydroquinolone compound, JAG21, has been discovered to eliminate both active and dormant forms of Toxoplasma gondii and P. falciparum parasites. The compound shows promise in treating toxoplasmosis and malaria, with the potential to prevent and cure all life-cycle stages of malaria.
Researchers discovered Plasmodium parasites use internal clocks to regulate gene expression and cell cycle activities in response to host signals. The finding of a genetic metronome and SR10 receptor protein could lead to novel drug targets for combating malaria.
A new study found that an indoor residual spray made from volcanic glass is effective in controlling mosquitoes carrying malaria. The spray, called Imergard WP, shows mortality rates of over 80% against both wild and susceptible strains of Anopheles gambiae mosquitoes.
A recent study found that the international trade in timber, tobacco, cocoa, coffee, and cotton significantly contributes to malaria risk in countries with deforestation hotspots. The research linked over 10% of malaria cases to demand from developed countries for these commodities.
Extracellular vesicles play a key role in the pathology of malaria vivax by promoting parasite adhesion to human spleen fibroblasts. The study found that EVs induce the expression of ICAM-1 on fibroblast surfaces, serving as an anchor for parasite-infected red blood cell adherence.
A new blood test has been developed to detect recent Plasmodium vivax infections and identify individuals with hypnozoites, which can cause relapsing malaria. The test offers high sensitivity and specificity, and mathematical models suggest it could reduce P. vivax prevalence by 59-69%.
Two malaria vaccines developed using genetically engineered malaria parasites have shown safety and preliminary protection in phase 1/2a clinical trials. The vaccines, created by Isaie Reuling and Meta Roestenberg teams, delayed infections when exposed to mosquitoes infected with Plasmodium falciparum, the primary cause of malaria in h...
A genetically modified malaria vaccine has been found to be safe and elicit a defense response against malaria infection in humans. The vaccine, developed with the American company Sanaria Inc., targets the liver stage of the disease and was administered to 67 volunteers, showing promising results.
Research reveals that malaria parasite P. vivax adheres to human spleen cells via variant proteins, allowing it to hide from the immune system and evade elimination. This finding suggests a double role for the spleen in malaria pathology and opens new avenues for vaccine targets and exposure markers.
Scientists have discovered that malaria's characteristic cycle of fever and chills is controlled by an intrinsic biological oscillator within the parasite. The study found that 87-92% of tracked genes were cyclical, providing strong evidence for an innate control mechanism.
Researchers discovered that malaria parasites can tick their own internal clocks, with 90% of genes showing rhythmic patterns. This internal metronome may help the parasite synchronize its escape from red blood cells and evade the human immune system.
Scientists have discovered that malaria parasites have an intrinsic clock controlling their invasion of human cells. This finding opens up new avenues for treating the disease by disrupting its biological rhythms.
Researchers found that the malaria parasite, P. falciparum, has a 48-hour developmental cycle with synchronous release of parasites from red blood cells, triggering fever cycles in humans. The study suggests that parasites have evolved mechanisms to precisely maintain periodicity.
Research found that malaria parasites have an inherent clock that drives their activity, resulting in cyclical fevers in humans. The parasite's gene expression patterns remained consistent despite changes in lighting conditions and host circadian rhythms.
A recent study using lidar technology reveals that mosquitoes are most active during morning and evening hours in Tanzania, with males being 87 times more active than usual. This finding suggests that light levels affect mosquito behavior, creating opportunities for developing light-based measures to prevent malaria.
Melbourne researchers have identified a microscopic protein, RPL6, that can be added to a malaria vaccine for efficient protection. The combination offered complete protection against malaria in mice, building upon the 2016 discovery of T cells resident in the liver and the 'prime and trap' vaccination strategy.
Scientists at Imperial College London used gene drive technology to create an all-male population of malaria-carrying mosquitoes, leading to a total collapse in the population. The modified mosquitoes produce more male offspring, causing females to be born and eventually leading to no females being present.
A new diagnostic approach in malaria has been adapted to track immunity to COVID-19, providing valuable details about when a person was exposed to the infection. The test can pinpoint how long ago a person was exposed, making it essential for tracking the spread of an infection and monitoring the effectiveness of control programs.
A new computational method, Souporcell, can accurately separate single-cell RNA sequencing data from multiple individuals without prior genome information. This enables researchers to study the effects of genetic variants on gene expression during infection or response to drugs.
A new study found that mosquitoes are most likely to transmit malaria in the early evening when people are exposed, followed by midnight and morning. This shift in biting behavior could reduce the effectiveness of bed nets in preventing malaria.
A meta-analysis of existing data from 4,968 pregnant women found that artemisinin-based combination therapies (ACTs) were significantly more effective than quinine in treating malaria. ACTs had better tolerability, with a lower risk of side effects, making them a safer option for pregnant women.
A study found that artemisinin-based combination therapies (ACTs) were significantly more effective than quinine in treating malaria in pregnant women. ACTs, such as artemether-lumefantrine, showed better tolerability and efficacy compared to quinine, with lower recurrence rates of malaria after treatment.
Strategies treating households near recent malaria cases with anti-malarial drugs and insecticides significantly reduce malaria in low-transmission settings. Researchers found that reactive focal mass drug administration (rfMDA) and reactive focal vector control (RAVC), used separately or together, can cut new cases by up to 75%.
Red blood cells deform and recover when passing through tiny channels, revealing a possible new method to diagnose diseases such as malaria. The researchers found that the shape recovery behavior depends on flow speed, viscosity, and elastic properties of the cell's outer membrane.
Researchers in Namibia demonstrated the effectiveness of targeting high-risk individuals with anti-malarial drugs and insecticide spraying to reduce malaria transmission. The trial, conducted in a low-endemic setting, showed a significant reduction in cases by up to 75%.
Researchers have identified a promising new strategy for combating malaria by targeting the parasite's 'kill switch' with PfGARP antibodies. The approach, which involves generating anti-PfGARP antibodies or directly infusing them into individuals, has shown promise in nonhuman primates and holds hope for preventing severe malaria.
Researchers at UC Davis cleared a major obstacle to using CRISPR-Cas9 gene drive technology to control mosquito-borne diseases. A study found that 90% of protein-coding genes in mosquito populations have suitable target sequences for the gene drive, making it effective against disease-causing viruses and parasites.
Researchers have identified how a deadly malaria parasite controls its stickiness in red blood cells, evading the immune system. By targeting this mechanism, potentially more effective therapies may be developed to combat the disease.
A new anti-malarial compound called SJ733 has shown promising results in its first clinical trial, demonstrating a rapid and effective treatment against malaria parasites. The study involved 38 healthy volunteers who received the drug after being infected with malaria, with no significant side effects identified.
The study of 1,100 people with uncomplicated falciparum malaria from eight countries shows that TACTs are highly efficacious with no safety concerns. However, they showed slightly higher rates of vomiting and minor changes in the electrical activity of the heart compared to existing treatment.
A study by University of Sydney and University of São Paulo found that 20% of malaria risk in deforestation hotspots is driven by international trade of goods like coffee, timber, and palm oil. The research calls for consumers to be more mindful of their consumption and procurement, supporting sustainable land ownership in developing c...
A new class of antimalarial compounds has been developed by Australian and US researchers, targeting a previously unexplored parasite pathway. The compounds have shown effectiveness against different species of malaria parasites, including Plasmodium falciparum, at multiple stages of the parasite lifecycle.
The NIH Technology Accelerator Challenge aims to develop handheld, digital technologies for detecting diseases with high global impact. The challenge will focus on sickle cell disease, malaria, and anemia, addressing the need for accessible diagnostic tools in low-resource settings.
Researchers found that drugs targeting T cells may be effective in treating cerebral malaria, a deadly disease mainly affecting young children. The study suggests that CTLs damage brain blood vessels, leading to brain swelling and death.
Scientists have made a breakthrough in understanding the rapid reproduction of the malaria parasite by identifying crucial molecules involved in cell division. This discovery could pave the way for developing novel therapeutic strategies against the disease.
Researchers discovered EphA2 protein plays a crucial role in cerebral malaria by disrupting blood-brain barrier, leading to leaky brain and deadly symptoms. Blocking EphA2 with drugs may prevent disease in humans, offering hope for alleviating this condition.
A vaccine clinical trial for pregnant women with malaria has shown promising results, demonstrating safety and an appropriate immune response. The PRIMVAC vaccine was found to be well-tolerated and induced antibodies capable of recognizing the Plasmodium falciparum parasite.
Researchers are developing long-acting formulations for malaria and TB prevention, as well as a single-injection cure for hepatitis C. The project aims to improve patient adherence and reduce disease transmission in low- and middle-income countries.
Researchers have elucidated the atomic structure of the sugar-transporting-protein PfHT1 in Plasmodium falciparum, gaining insight into glucose uptake. This breakthrough could lead to the development of more specific and effective antimalarial compounds.
A Phase 1 clinical trial tests the safety and effectiveness of mAb CIS43LS in preventing malaria infection. Volunteers will receive a single dose of the antibody and then be exposed to malaria-carrying mosquitoes to assess protection.
A novel malaria vaccine candidate based on the tobacco mosaic virus has shown a 10X improvement over a comparator vaccine in mouse trials. The vaccine uses the TMV coat protein as a scaffold to refocus the host immune system, offering protection against Plasmodium falciparum malaria up to 11 months.
A team of researchers developed a promising tool to combat malaria and other mosquito-borne diseases. Their genetically engineered fungus toxin killed 75% of insecticide-resistant mosquitoes, causing an established population to collapse within 45 days.
Researchers have discovered a rare African-specific variant of the TP53 gene that causes iron accumulation in macrophages, leading to poorer responses to bacterial infections. However, this variant also improves response to malaria toxin, potentially offering protection against severe inflammation and disease severity.
Researchers created 3D human capillaries to study how red blood cells navigate ultra-small blood vessels. Malaria-infected cells become stalled due to shape and motion changes, increasing risk of adherence and blockage.
A comprehensive roadmap has been established to evaluate and implement ivermectin as a complementary vector control tool against malaria. The roadmap aims to decrease malaria transmission by targeting the vector population, bypassing challenges of insecticide resistance and residual transmission.
Dou's research aims to disrupt the parasite's nutrient metabolism, potentially leading to new drug treatments for toxoplasmosis and malaria. The grant will explore the molecular mechanisms of Toxoplasma gondii, a parasite that affects over 40 million people worldwide.